Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.87 USD | -2.60% | -3.61% | +20.65% |
Financials (USD)
Sales 2024 * | 108M | Sales 2025 * | 76.06M | Capitalization | 146M |
---|---|---|---|---|---|
Net income 2024 * | -17M | Net income 2025 * | -50M | EV / Sales 2024 * | 1.35 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.92 x |
P/E ratio 2024 * |
-9.27
x | P/E ratio 2025 * |
-3.91
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.97% |
Latest transcript on CytomX Therapeutics, Inc.
1 day | -2.60% | ||
1 week | -3.61% | ||
Current month | +14.72% | ||
1 month | +11.98% | ||
3 months | +28.97% | ||
6 months | +43.30% | ||
Current year | +20.65% |
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 21-08-01 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 59 | 18-12-19 |
Elaine Jones
BRD | Director/Board Member | 69 | 14-11-30 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 1.87 | -2.60% | 1,513,123 |
24-05-20 | 1.92 | +1.59% | 1,662,904 |
24-05-17 | 1.89 | -5.50% | 3,538,621 |
24-05-16 | 2 | +2.04% | 3,288,698 |
24-05-15 | 1.96 | +1.03% | 3,922,236 |
Delayed Quote Nasdaq, May 21, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.65% | 150M | |
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |
- Stock Market
- Equities
- CTMX Stock